Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 425, 357-359 (25 September 2003) | doi:10.1038/425357a
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
nature jobs
Senior Scientist, Cellular & Molecular Pharmacology
- Cortex Search Inc.
- Vancouver, British Columbia
Postdoctoral Researchers / Graduate Research Assistant - Center for Physical Activity and Weight Management
- University of Kansas
- Lawrence and Kansas City, KS
Cancer: The rules of attraction
Abstract
The puzzle of how a drug that binds to a protein found in normal cells as well as cancer cells preferentially kills tumours is now solved — the target protein exists in a drug-binding complex in tumour cells.
Targeting a specific protein or a single signalling pathway that is required for the survival of tumour cells but not normal cells would seem to be a promising anticancer strategy. Unfortunately, few such unique targets exist, and it is becoming clear that inhibiting a single pathway might not be enough to tackle cancers that result from several genetic abnormalities.
- Len Neckers is in the Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Yong-Sok Lee is in the Center for Molecular Modelling, Center for Information Technology, National Institutes of Health, Bethesda, Maryland 20892, USA.
Correspondence to: Len Neckers1 Email: len@helix.nih.gov
To read this story in full you will need to login or make a payment (see right).

